X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Orchid Chemicals with AJANTA PHARMA - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

ORCHID PHARMA LTD vs AJANTA PHARMA - Comparison Results

ORCHID PHARMA LTD    Change

Orchid Chemicals & Pharmaceuticals Ltd. (Orchid) is today a globally recognized, integrated pharmaceutical company with core competencies in the development and manufacture of Active Pharmaceutical Ingredients (APIs) and Finished Dosage Forms as well... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    ORCHID PHARMA LTD AJANTA PHARMA ORCHID PHARMA LTD/
AJANTA PHARMA
 
P/E (TTM) x 0.2 21.4 0.7% View Chart
P/BV x 0.2 5.0 3.6% View Chart
Dividend Yield % 0.0 0.0 -  

Financials

 ORCHID PHARMA LTD   AJANTA PHARMA
EQUITY SHARE DATA
    ORCHID PHARMA LTD
Sep-13
AJANTA PHARMA
Mar-18
ORCHID PHARMA LTD/
AJANTA PHARMA
5-Yr Chart
Click to enlarge
High Rs1941,818 10.7%   
Low Rs351,106 3.2%   
Sales per share (Unadj.) Rs276.5239.5 115.4%  
Earnings per share (Unadj.) Rs-79.252.8 -150.0%  
Cash flow per share (Unadj.) Rs-43.559.5 -73.0%  
Dividends per share (Unadj.) Rs00-  
Dividend yield (eoy) %00-  
Book value per share (Unadj.) Rs53.9230.0 23.5%  
Shares outstanding (eoy) m70.4588.77 79.4%   
Bonus/Rights/Conversions ESOP--  
Price / Sales ratio x0.46.1 6.8%   
Avg P/E ratio x-1.427.7 -5.2%  
P/CF ratio (eoy) x-2.624.6 -10.7%  
Price / Book Value ratio x2.16.4 33.4%  
Dividend payout %00-   
Avg Mkt Cap Rs m8,067129,782 6.2%   
No. of employees `0002.86.8 41.2%   
Total wages/salary Rs m2,5273,765 67.1%   
Avg. sales/employee Rs Th6,956.13,128.4 222.4%   
Avg. wages/employee Rs Th902.5554.0 162.9%   
Avg. net profit/employee Rs Th-1,993.0689.7 -289.0%   
INCOME DATA
Net Sales Rs m19,47721,258 91.6%  
Other income Rs m407242 168.5%   
Total revenues Rs m19,88421,499 92.5%   
Gross profit Rs m1,1036,584 16.7%  
Depreciation Rs m2,519596 422.8%   
Interest Rs m5,2274 127,482.9%   
Profit before tax Rs m-6,2366,226 -100.2%   
Minority Interest Rs m200-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m5110-   
Tax Rs m-1251,539 -8.1%   
Profit after tax Rs m-5,5804,686 -119.1%  
Gross profit margin %5.731.0 18.3%  
Effective tax rate %2.024.7 8.1%   
Net profit margin %-28.722.0 -130.0%  
BALANCE SHEET DATA
Current assets Rs m11,01412,236 90.0%   
Current liabilities Rs m32,0603,461 926.5%   
Net working cap to sales %-108.141.3 -261.7%  
Current ratio x0.33.5 9.7%  
Inventory Days Days9560 157.6%  
Debtors Days Days3484 39.7%  
Net fixed assets Rs m29,44011,140 264.3%   
Share capital Rs m705177 398.2%   
"Free" reserves Rs m2,04320,237 10.1%   
Net worth Rs m3,80020,414 18.6%   
Long term debt Rs m9,01810 89,286.1%   
Total assets Rs m46,51024,486 189.9%  
Interest coverage x-0.21,519.4 -0.0%   
Debt to equity ratio x2.40 479,660.1%  
Sales to assets ratio x0.40.9 48.2%   
Return on assets %-0.819.2 -4.0%  
Return on equity %-146.923.0 -639.7%  
Return on capital %-3.730.5 -12.2%  
Exports to sales %37.90-   
Imports to sales %22.60-   
Exports (fob) Rs m7,378NA-   
Imports (cif) Rs m4,406NA-   
Fx inflow Rs m7,51311,667 64.4%   
Fx outflow Rs m5,6491,616 349.7%   
Net fx Rs m1,86510,052 18.5%   
CASH FLOW
From Operations Rs m1,6822,854 58.9%  
From Investments Rs m-9,860-2,604 378.6%  
From Financial Activity Rs m6,644-2 -332,190.0%  
Net Cashflow Rs m-1,535248 -618.7%  

Share Holding

Indian Promoters % 32.3 73.8 43.8%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 4.6 1.6 296.8%  
FIIs % 3.3 7.6 43.4%  
ADR/GDR % 4.6 0.0 -  
Free float % 55.3 17.0 325.3%  
Shareholders   84,811 20,968 404.5%  
Pledged promoter(s) holding % 54.9 4.4 1,251.0%  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare ORCHID PHARMA LTD With:   BIOCON LTD  WOCKHARDT LTD.  VENUS REMEDIES  PLETHICO PHARMA  GLENMARK PHARMA  

Compare ORCHID PHARMA LTD With:   ADCOCK INGRAM (S. Africa)  MYLAN (US)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex Ends 207 Points Higher; Healthcare Stocks Witness Buying(Closing)

Indian share markets continued to trade in the green during the closing hours of the trading session and ended the day on a positive note.

Related Views on News

AJANTA PHARMA Announces Quarterly Results (1QFY19); Net Profit Up 11.6% (Quarterly Result Update)

Aug 1, 2018 | Updated on Aug 1, 2018

For the quarter ended June 2018, AJANTA PHARMA has posted a net profit of Rs 1 bn (up 11.6% YoY). Sales on the other hand came in at Rs 5 bn (up 8.0% YoY). Read on for a complete analysis of AJANTA PHARMA's quarterly results.

AJANTA PHARMA Announces Quarterly Results (4QFY18); Net Profit Down 17.1% (Quarterly Result Update)

Jul 20, 2018 | Updated on Jul 20, 2018

For the quarter ended March 2018, AJANTA PHARMA has posted a net profit of Rs 945 m (down 17.1% YoY). Sales on the other hand came in at Rs 5 bn (up 11.2% YoY). Read on for a complete analysis of AJANTA PHARMA's quarterly results.

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

More Views on News

Most Popular

How to Make Big Profits by Following India's Best Investors(The 5 Minute Wrapup)

Aug 3, 2018

In a time when stocks recommended by so-called 'gurus of the market' are crashing, let Kunal Thanvi guide you to the best gurus...and their best stocks.

The Biggest Mistake You Can Make in this Market (and 3 Stocks to Buy Now!)(Profit Hunter)

Aug 3, 2018

This price pattern can help you identify stocks on the verge of a turnaround.

Does This Indicator Tell Us the Sensex is Headed for a Correction?(Vivek Kaul's Diary)

Aug 3, 2018

To what extent have foreign flows influenced Indian stock markets? How do we see it panning out now?

Is Franklin India Smaller Companies Fund Worth Your Money(Outside View)

Aug 2, 2018

Although positioned as a small cap fund, Franklin India Smaller Companies Fund has been investing a significant portion of its assets in mid-caps along with a nominal exposure to large caps.

Why HDFC Equity Fund Disappointed Its Investors(Outside View)

Aug 9, 2018

Though popular, HDFC Equity Fund is not among the best performers anymore. Here is the reason behind its underperformance that has left investors disappointed.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

ORCHID PHARMA LTD SHARE PRICE


Aug 14, 2018 (Close)

TRACK ORCHID PHARMA LTD

  • Track your investment in ORCHID PHARMA LTD with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON ORCHID PHARMA LTD

ORCHID PHARMA LTD - DR. DATSONS LABS COMPARISON

COMPARE ORCHID PHARMA LTD WITH

MARKET STATS